EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase IV)Open Access · CC BY 4.0

A fixed dose combination of tamsulosin and tadalafil in men with benign prostatic hyperplasia and erectile dysfunction: a prospective, multicenter, phase IV study

Chirag Gupta, Avinash T S, Dushyant Shamlabhai Pawar, Abhay Khandekar, G Ravindra Deshmukh, Vinay Kumar, Ajwani Vikky Ramesh, Shah Ishan Hemantkumar, Patankar Suresh Balkrishna, Mandodari Rajurkar, Dipesh Sonawane, Dipak Patil und 2 weitere

World Journal of Urology · 2026

DOI: 10.1007/s00345-026-06306-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift World Journal of Urology, 2026. Verfasst von Chirag Gupta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Jaipur National University Institute for Medical Science and Research Center, Jaipur, Rajasthan, India. Hauptthemen laut MEDLINE: Tadalafil, Tamsulosin, Prostatic Hyperplasia, Erectile Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sun Pharma Laboratories Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the safety and efficacy of a fixed-dose combination (FDC) of tamsulosin prolonged release (PR) and tadalafil in moderate-severe benign prostatic hyperplasia (BPH) and erectile dysfunction (ED).

Methods

This was a single-arm, phase IV, prospective clinical trial in sexually active men aged 45–75 years with BPH [International Prostate Symptom Score (IPSS) score ≥ 8] and ED [International Index of Erectile Function-Erectile Function (IIEF-EF) score ≤ 25] who were taking tamsulosin 0.4 mg PR and tadalafil 5 mg. Eligible patients received FDC of tamsulosin+tadalafil (0.4 + 5 mg) capsules for 12 weeks. The endpoints included treatment-emergent adverse events (TEAEs), total IPSS, IPSS storage and voiding sub-scores, maximum urinary flow rate (Q max ), post-void residual (PVR) volume, IIEF-EF (questions 1–5 and 15) score, and IPSS quality of life (QoL) index.

Results

A total of 172 were enrolled. Overall, 12 TEAEs were reported in 10 (5.81%) patients. None of the TEAEs were severe, serious, life-threatening, or required treatment interruption. A statistically significant improvement ( p < 0.0001) in total IPSS after 4, 8, and 12 weeks was observed. Similar improvements from baseline were also observed in IPSS storage and voiding sub-scores, IPSS QoL, Q max , PVR volume, and IIEF-EF (questions 1–5 and 15) score ( p < 0.05 for each parameter). The proportion of men with normal erectile function significantly increased at week 12 ( p = 0.0003).

Conclusion

The FDC of tamsulosin and tadalafil was associated with significant improvements in lower urinary tract symptoms and EF over 12 weeks and was well tolerated in Indian men with moderate-severe BPH and ED.

Trial registration

Prospectively registered at Clinical Trials Registry—India on 10th June 2022 [CTRI/2022/06/043152].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TadalafilTamsulosinProstatic HyperplasiaErectile DysfunctionPhosphodiesterase 5 InhibitorsHumansMaleMiddle AgedProspective StudiesAgedDrug CombinationsTreatment Outcome

Stichwörter der Autor:innen

Benign prostatic hyperplasiaErectile dysfunctionInternational prostate symptom scoreLower urinary tract symptomsTadalafilTamsulosin

Substanzen

TadalafilTamsulosinPhosphodiesterase 5 InhibitorsDrug Combinations

Autor:innen und Institutionen

  • Department of Urology, Jaipur National University Institute for Medical Science and Research Center, Jaipur, Rajasthan, India.
  • Department of Urology, Sparsh Super Specialty Hospital, Bangalore, Karnataka, India.
  • Department of Urology, Indus Hospital, Ahmedabad, Gujarat, India.
  • Department of Urology, Siddhivinayak Hospital, Ahmedabad, Gujarat, India.
  • Department of Urology, Jasleen Hospital, Nagpur, Maharashtra, India.
  • Department of Surgery, GSVM Medical College, Kanpur, Uttar Pradesh, India.

Förderung

  • Sun Pharma Laboratories Limited

Zitieren

APA

Gupta, C., S, A. T., Pawar, D. S., Khandekar, A., Deshmukh, G. R., Kumar, V., Ramesh, A. V., Hemantkumar, S. I., Balkrishna, P. S., Rajurkar, M., Sonawane, D., Patil, D., Ghadge, P., & Mehta, S. (2026). A fixed dose combination of tamsulosin and tadalafil in men with benign prostatic hyperplasia and erectile dysfunction: a prospective, multicenter, phase IV study. World Journal of Urology. https://doi.org/10.1007/s00345-026-06306-3

Vancouver

Gupta C, S AT, Pawar DS, Khandekar A, Deshmukh GR, Kumar V, et al. A fixed dose combination of tamsulosin and tadalafil in men with benign prostatic hyperplasia and erectile dysfunction: a prospective, multicenter, phase IV study. World Journal of Urology. 2026. doi:10.1007/s00345-026-06306-3

BibTeX
@article{Gupta2026,
  author = {Gupta, Chirag and S, Avinash T and Pawar, Dushyant Shamlabhai and Khandekar, Abhay and Deshmukh, G Ravindra and Kumar, Vinay and Ramesh, Ajwani Vikky and Hemantkumar, Shah Ishan and Balkrishna, Patankar Suresh and Rajurkar, Mandodari and Sonawane, Dipesh and Patil, Dipak and Ghadge, Pravin and Mehta, Suyog},
  title = {A fixed dose combination of tamsulosin and tadalafil in men with benign prostatic hyperplasia and erectile dysfunction: a prospective, multicenter, phase IV study},
  journal = {World Journal of Urology},
  year = {2026},
  doi = {10.1007/s00345-026-06306-3}
}
Kostenlos starten →